ECCMID: The value of calprotectin in the Emergency Department
13. Apr 2023 |
6 min read
Learn more about the value of calprotectin in the Emergency Department
Studies have shown the ability of calprotectin to predict bacterial infections before onset of clinical symptoms and distinguish between bacterial and viral infections, with high sensitivity and specificity. With early diagnosis of bacterial infections delayed treatment will be avoided as well as deterioration due to severe infections, including sepsis1-3.
Calprotectin in acute infections and sepsis for prognosis, characterisation and diagnosis in the Emergency Department
We are pleased to present results from a prospective clinical trial in collaboration with Charité – Universitätsmedizin Berlin and Labor Berlin.
Join us at the Innovation Theatre April 17th at 14:30 to get insight to results from the CASCADE-Trial.
The Innovation Theatre is located behind Hall C, opposite to Hall B.
Dr. Wolfgang Bauer, PI of the trial with title “Calprotectin in Acute Infections and Sepsis for Prognosis, Characterisation and Diagnosis in the Emergency Department” (CASCADE-Trial) will present results from the study and discuss the value of calprotectin for diagnosis and management of acute infections and sepsis in the Emergency Department.
Plasma Calprotectin as a biomarker for infection and sepsis
The results from the the CASCADEtrial (*Calprotectin in Acute Infections and Sepsis for Prognosis, Characterization and Diagnosis in the Emergency Department) will also be presented as a poster at ECCMID. The prospective and observational trial aims to evaluate the role of calprotectin in detection/prediction of infection and estimation of the disease severity/outcome in patients presented at the Emergency Department. The accuracy of calprotectin in prediction of bacterial infection, multiorgan failure, sepsis and mortality has been analysed and compared to routinely used biomarkers and scores.
Cost-effectiveness of GCAL® Calprotectin Immunoassay in early diagnosis of bacterial infections in intensive care patients*
Gentian's CSO Aleksandra Havelka will presents results from a study on health economic impact of use of calprotectin for early detection of infection in intensive care patients. The analysis is based on patients admitted to an Intensive Care Unit (ICU) in a Swedish hospital through a decision tree model. The model is employed to estimate the cost-effectiveness of calprotectin analysis for early detection of bacterial infection and thus, the earlier start of antibiotic treatment compared to other diagnostic biomarkers. The comparators included in the analysis are white blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP), and no testing. The study used Gentian's GCAL® Calprotectin Immunoassay.
Contact us for further information about calprotectin and the GCAL® assay
Explore GCAL® in your clinical practice and laboratory - fill out the form or send an email to email@example.com for more information about the product and prices.
*Authors Havelka, A.1, 2, M. Lipcsey 3, 4, M. Hultström 3, 5, A. Larsson 6.
1) Department of Molecular Medicine and Surgery, Karolinska Institute - Stockholm (Sweden), 2) Gentian Diagnostics AB - Stockholm (Sweden), 3) Department of Surgical Sciences, Anesthesiology, Uppsala University - Uppsala (Sweden), 4) Hedenstierna laboratory, Anesthesiology and Intensive care, Uppsala University - Uppsala (Sweden), 5) Integrative Physiology, Department of Medical Cell Biology - Uppsala (Sweden), 6) Department of Medical Sciences, Clinical Chemistry, Akademiska University Hospital - Uppsala (Sweden)